Actively Recruiting
National Longitudinal Study on Autoimmune Hemolytic Anemia in China Tracking Patient Characteristics, Treatments, and Outcomes
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17
9999
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating autoimmune hemolytic anemia AIHA, a disorder affecting the blood and blood-forming organs. This study aims to understand the incidence and risk factors of AIHA in China and to analyze treatment effectiveness, patient outcomes, and healthcare costs. It addresses the need for a comprehensive, large-scale prospective cohort study in hematology, as previous cohorts have been limited in size or scope. The study involves a combined retrospective and prospective observational follow-up approach. Researchers will collect detailed patient information from medical records, including diagnosis, treatment, and healthcare costs. Questionnaires will be used to gather patient exposure data, while ongoing follow-up will capture prognosis information over time. Participants diagnosed with AIHA will be tracked at various points, with hematologic response assessed at baseline, 6 months, 12 months, 24 months after treatment, and at study completion. The study will also evaluate relapse rates, mortality, long-term prognosis, and quality of life. Data collection focuses on demographic and clinical features, treatment patterns, and real-world outcomes.
CONDITIONS
Brief Title
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Research Team
L
Lele Zhang, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here